SCHEMBL1199775

SCHEMBL1199775

CCOP(=O)(O)CC(C)=O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.52
TSHR P16473 2/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
PGGT1B P53609 1/20 0.41
TDP1 Q9NUW8 2/20 0.39
TP53 P04637 1/20 0.39
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
BTN3A1 O00481 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7597273 0.81 PPARD (0.52) PPARDTSHRFNTAFNTBPGGT1B
SCHEMBL10388124 0.79 PPARD (0.50) PPARDTSHRFNTAFNTBPGGT1B
SCHEMBL17860875 0.79 CYP3A4 (0.50) TSHRALDH1A1
SCHEMBL246813 0.78 TSHR (0.52) PPARDTSHRTDP1TP53CA12
SCHEMBL418898 0.77 PPARD (0.48) PPARDTSHRFNTAFNTBPGGT1B
SCHEMBL2640099 0.77 PPARD (0.48) PPARDTSHRFNTAFNTBPGGT1B
SCHEMBL11913313 0.76 TDP1 (0.44) PPARDTSHRTDP1TP53CA12
Acetic Acid SCHEMBL27613905 0.76 PPARD (0.52) PPARDTSHRFNTAFNTBPGGT1B
SCHEMBL3939887 0.76 PPARD (0.47) PPARDTSHRFNTAFNTBPGGT1B
SCHEMBL28916777 0.76 ENO1 (0.52) PPARDTSHRFNTAFNTBPGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017059411-A9 INHIBITORS OF MENAQUINONE BIOSYNTHESIS MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2017-08-31 WO disclosed
US-20150038460-A1 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor GENENTECH, INC. (US) 2015-02-05 US disclosed
US-8901313-B2 6,5-heterocyclic propargylic alcohol compounds and uses therefor GENENTECH, INC. (US) 2014-12-02 US disclosed
EP-2686314-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR F.HOFFMANN-LA ROCHE AG (CH) 2014-01-22 EP disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
US-20120295856-A1 FREDERICAMYCIN DERIVATIVES ZENTOPHARM GMBH (DE) 2012-11-22 US disclosed
WO-2012123522-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO disclosed
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR GENENTECH, INC. (US) 2012-08-23 US disclosed
US-8247424-B2 Water soluble groups on ring A; antitumor antibiotics; 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3-yl]pentitol; topoisomerase inhibitors; cyclodextrin inclusions; stereoisomers ZENTOPHARM GMBH (DE) 2012-08-21 US disclosed
US-8066914-B2 7-ethynyl-2,4,9-trithiaadamantane and related methods UNIVERSITY OF AKRON (US) 2011-11-29 US disclosed
US-20050256066-A1 Water soluble groups on ring A; antitumor antibiotics; 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3-yl]pentitol; topoisomerase inhibitors; cyclodextrin inclusions; stereoisomers BIOFRONTERA DISCOVERY GMBH (DE) 2005-11-17 US disclosed
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists ELI LILLY COMPANY (US) 2005-10-27 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501809-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2005003089-A2 7-ETHYNYL-2,4,9-TRITHIAADAMANTANE AND RELATED METHODS THE UNIVERSITY OF AKRON (US) 2005-01-13 WO disclosed
WO-2004103985-A2 DERIVATIVES OF FUSAROCHROMANONE AS THERAPEUTIC AGENTS UNIVERSITY OF SOUTH CAROLINA (US) 2004-12-02 WO disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed
WO-2003091226-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed
US-20030096875-A1 Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents CHEMAPHOR INC. (CA) 2003-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists TACR1, TACR2, BDKRB1 PPARD 3932/4885TSHR 251/4885FNTA 3387/4885
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 PPARD 3887/4885TSHR 337/4885FNTA 4427/4885
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR NFKB1, NFRKB, NFKBIA PPARD 1480/4885TSHR 1966/4885FNTA 864/4885
US-20120295856-A1 FREDERICAMYCIN DERIVATIVES NISCH, MYC, MANBA PPARD 2687/4885TSHR 4691/4885FNTA 90/4885
US-20030096875-A1 Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents HCCS, MKI67, ALDH1A2 PPARD 754/4885TSHR 4378/4885FNTA 1501/4885
US-20050256066-A1 Water soluble groups on ring A; antitumor antibiotics; 1-Desoxy-5-C-[(8R)-4',9,9'-trihydroxy-6'-methoxy-1,1',3',5',8'-pentaoxo-1,1',2,3',5',6,7,8'-octahydrospiro[cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]-naphthalene]-3-yl]pentitol; topoisomerase inhibitors; cyclodextrin inclusions; stereoisomers TOP1, TOP2A, TOP2B PPARD 3968/4885TSHR 4289/4885FNTA 892/4885
US-20150038460-A1 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor NFKB1, NFRKB, NFKBIA PPARD 1480/4885TSHR 1966/4885FNTA 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.